Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nordmark Pharma GmbH has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner and a distinct art unit. EDWARDS, JESSICA FAYE is the busiest examiner for the portfolio and manages the 1 pending office action. The art unit assignment reflects the technical classification of the company's current filing. Practitioners should monitor the busiest examiner for updates on the pending matter. The current administrative footprint is limited to a point of review within the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EDWARDS, JESSICA FAYE | 1 | 38.3% | +47.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430071 | CHROMATOGRAPHIC PURIFICATION OF AT LEAST ONE ENZYME SELECTED FROM A GROUP INCLUDING COLLAGENASE TYPE I, COLLAGENASE TYPE II, NEUTRAL PROTEASE AND CLOSTRIPAIN | EDWARDS, JESSICA FAYE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430071 | CHROMATOGRAPHIC PURIFICATION OF AT LEAST ONE ENZYME SELECTED FROM A GROUP INCLUDING COLLAGENASE TYPE I, COLLAGENASE TYPE II, NEUTRAL PROTEASE AND CLOSTRIPAIN | EDWARDS, JESSICA FAYE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17430071 | CHROMATOGRAPHIC PURIFICATION OF AT LEAST ONE ENZYME SELECTED FROM A GROUP INCLUDING COLLAGENASE TYPE I, COLLAGENASE TYPE II, NEUTRAL PROTEASE AND CLOSTRIPAIN | EDWARDS, JESSICA FAYE | 1657 | §103§112 | Final Rejection | — | Pending | Aug 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNordmark Pharma GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jessica Faye Edwards has the most, with 1 of Nordmark Pharma GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
